Table 2 Efficacy of three artemisinin-containing combinations therapy in comparison with amodiaquine + sulphadoxine–pyrimethamine (AQ-SP) on day 28 after PCR correction, per-protocol analysis
AS-SMP N = 54 | AS-AQ N = 59 | AL N = 52 | AQ-SP N = 57 | p-value | ||
|---|---|---|---|---|---|---|
Per protocol analysis (with PCR correction) | ||||||
ETF | ||||||
n % (95% CI) | 1 2% (0–10) | 0 0% (0–6) | 0 0% (0–7) | 0 0% (0–6) | ||
LCF | ||||||
n % (95% CI) | 2 4% (0–13) | 3 5% (1–14) | 2 4% (0–13) | 0 0% (0–6) | ||
LPF | ||||||
n % (95% CI) | 1 2% (0–10) | 1 2% (0–9) | 2 4% (0–13) | 0 0% (0–6) | ||
ACPR | 0.133 | |||||
n % (95% CI) | 50 93% (82–98) | 55 93% (84–98) | 52 92% (81–98) | 57 100% (94–100) | ||
Intention to treat analysis (without PCR correction) | ||||||
ETF | ||||||
n % (95% CI) | 1 2% (0–9) | 0 0% (0–5) | 0 0% (0–6) | 0 0% (0–6) | ||
LCF | ||||||
n % (95% CI) | 6 10% (4–21) | 3 4% (1–12) | 2 3%(0–12) | 0 0% (0–6) | ||
LPF | ||||||
n % (95% CI) | 1 2% (0–9) | 1 1% (0–8) | 3 5% (1–14) | 1 2% (0–8) | ||
ACPR | ||||||
n % (95% CI) | 48 83% (71–91) | 55 81% (70–89) | 48 80% (68–89) | 57 88%(77–95) | 0.058 |